XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) and Addex Therapeutics (NASDAQ:ADXN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.
Earnings & Valuation
This table compares XORTX Therapeutics and Addex Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XORTX Therapeutics | N/A | N/A | -$2.66 million | ($2.63) | -0.83 |
| Addex Therapeutics | $210,000.00 | 37.78 | -$8.12 million | ($5.74) | -1.12 |
Analyst Recommendations
This is a summary of current ratings and price targets for XORTX Therapeutics and Addex Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XORTX Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Addex Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares XORTX Therapeutics and Addex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XORTX Therapeutics | N/A | -150.01% | -106.53% |
| Addex Therapeutics | N/A | -105.98% | -87.61% |
Institutional & Insider Ownership
0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
XORTX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
Summary
Addex Therapeutics beats XORTX Therapeutics on 6 of the 9 factors compared between the two stocks.
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
